Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IV long-term evaluation of TO-194SL in Japanese cedar pollinosis
jRCT1080222534Phase 4Completed
- Sponsor
- Torii Pharmaceutical
- Start
- Jun 2014
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of japanese cedar pollen extract in Japanese cedar pollinosis and seasonal allergic rhinitis (SAR), sponsored by Torii Pharmaceutical. Started Jun 2014; status: completed.
02
Drugs
japanese cedar pollen extract
03
Conditions
Japanese cedar pollinosisseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT1080222534.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1080222534.